3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
29
Triple Negative Breast Neoplasms
13
Ovarian Neoplasms
5
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Metastatic Breast Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Recurrence
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Pathologic Complete Response
1
Mesothelioma
1
Hemangiosarcoma
1
Gastrointestinal Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Fallopian Tube Neoplasms
1
Carcinoma, Renal Cell
1
Breast Adenocarcinoma
1
Advanced Ovarian Cancer
1
Advanced Breast Cancer
1
Interventions
Trastuzumab
5
Carboplatin
5
Docetaxel
4
pertuzumab
3
Paclitaxel
3
Cyclophosphamide
3
pembrolizumab
2
Epirubicin
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
taxane
1
talazoparib
1
sarilumab
1
pyrotinib
1
pirarubicin
1
pexidartinib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
talazoparib
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled